Compare Stocks: ARTL, RVPH, CVKD, and ADXN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$5.66 -0.5%	$6.10	$5.04 ▼ $12.05	$6.97M	1.5	4,872 shs	1,614 shs
ARTL Artelo Biosciences	$0.77 +2.5%	$1.14	$0.71 ▼ $31.65	$1.80M	-0.07	1.90 million shs	53,693 shs
CVKD Cadrenal Therapeutics	$1.94 -1.0%	$3.08	$1.86 ▼ $14.64	$6.64M	1.84	61,251 shs	7,232 shs
RVPH Reviva Pharmaceuticals	$0.45	$0.58	$0.26 ▼ $17.20	$5.90M	0.53	411,256 shs	31,701 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	-9.81%	-9.07%	-14.54%	-23.93%	-38.69%
ARTL Artelo Biosciences	-1.80%	+3.86%	-31.07%	-71.97%	-97.36%
CVKD Cadrenal Therapeutics	-3.45%	-1.46%	-41.67%	-67.44%	-82.02%
RVPH Reviva Pharmaceuticals	-13.46%	+9.76%	-28.57%	-47.82%	-95.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$5.66 -0.5%	$6.10	$5.04 ▼ $12.05	$6.97M	1.5	4,872 shs	1,614 shs
ARTL Artelo Biosciences	$0.77 +2.5%	$1.14	$0.71 ▼ $31.65	$1.80M	-0.07	1.90 million shs	53,693 shs
CVKD Cadrenal Therapeutics	$1.94 -1.0%	$3.08	$1.86 ▼ $14.64	$6.64M	1.84	61,251 shs	7,232 shs
RVPH Reviva Pharmaceuticals	$0.45	$0.58	$0.26 ▼ $17.20	$5.90M	0.53	411,256 shs	31,701 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	-9.81%	-9.07%	-14.54%	-23.93%	-38.69%
ARTL Artelo Biosciences	-1.80%	+3.86%	-31.07%	-71.97%	-97.36%
CVKD Cadrenal Therapeutics	-3.45%	-1.46%	-41.67%	-67.44%	-82.02%
RVPH Reviva Pharmaceuticals	-13.46%	+9.76%	-28.57%	-47.82%	-95.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	1.00	Sell	N/A	N/A
ARTL Artelo Biosciences	1.67	Reduce	$54.00	6,912.99% Upside
CVKD Cadrenal Therapeutics	2.00	Hold	$13.00	569.76% Upside
RVPH Reviva Pharmaceuticals	2.50	Moderate Buy	$66.67	14,714.81% Upside

Current Analyst Ratings Breakdown

Latest ARTL, RVPH, CVKD, and ADXN Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/17/2026	CVKD Cadrenal Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	ADXN Addex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	ARTL Artelo Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$29.97K	232.65	N/A	N/A	$4.67 per share	1.21
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	($1.89) per share	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	$1.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	-$8.12M	-$5.94	N/A	N/A	N/A	N/A	-134.76%	-106.00%	8/24/2026 (Estimated)
ARTL Artelo Biosciences	-$12.88M	-$32.74	N/A	N/A	N/A	N/A	-1,600.12%	-224.62%	8/12/2026 (Estimated)
CVKD Cadrenal Therapeutics	-$13.24M	-$5.63	N/A	N/A	N/A	N/A	-411.03%	-275.61%	8/10/2026 (Estimated)
RVPH Reviva Pharmaceuticals	-$19.86M	-$4.06	N/A	N/A	N/A	N/A	-391.58%	-119.08%	8/13/2026 (Estimated)

Latest ARTL, RVPH, CVKD, and ADXN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	RVPH Reviva Pharmaceuticals	-$0.36	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	ARTL Artelo Biosciences	-$0.72	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	CVKD Cadrenal Therapeutics	-$1.42	N/A	N/A	N/A	N/A	N/A
5/14/2026	Q1 2026	ARTL Artelo Biosciences	-$0.78	-$4.00	-$3.22	-$4.00	N/A	N/A
5/14/2026	Q1 2026	RVPH Reviva Pharmaceuticals	-$0.3550	-$0.46	-$0.1050	-$0.46	N/A	N/A
5/7/2026	Q4 2025	CVKD Cadrenal Therapeutics	-$1.51	-$1.04	+$0.47	-$1.04	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	0.97	0.97
ARTL Artelo Biosciences	N/A	1.79	1.79
CVKD Cadrenal Therapeutics	N/A	2.68	2.68
RVPH Reviva Pharmaceuticals	N/A	2.08	2.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
ARTL Artelo Biosciences	0.87%
CVKD Cadrenal Therapeutics	7.92%
RVPH Reviva Pharmaceuticals	63.18%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
ARTL Artelo Biosciences	3.20%
CVKD Cadrenal Therapeutics	26.09%
RVPH Reviva Pharmaceuticals	8.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	30	1.23 million	1.05 million	Not Optionable
ARTL Artelo Biosciences	5	2.33 million	2.26 million	Not Optionable
CVKD Cadrenal Therapeutics	4	3.42 million	2.53 million	Not Optionable
RVPH Reviva Pharmaceuticals	5	13.11 million	11.67 million	Optionable

ARTL, RVPH, CVKD, and ADXN Headlines

Recent News About These Companies

Reviva Pharmaceuticals (RVPH) Expected to Post Quarterly Earnings on Thursday

August 6 at 2:56 AM | americanbankingnews.com

Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th

June 23, 2026 | financialpost.comF

Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th

June 23, 2026 | globenewswire.com

Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase

May 18, 2026 | finance.yahoo.com

Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase

May 18, 2026 | globenewswire.com

OTC Listing Leaves Reviva Pharmaceuticals Shares Vulnerable to Thin Trading and Volatile Price Swings

May 15, 2026 | tipranks.com

Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Merck & Company (MRK)

April 21, 2026 | theglobeandmail.com

Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans

April 20, 2026 | insidermonkey.com

Reviva Pharmaceuticals: Reviva Announces Letter to Shareholders

April 15, 2026 | finanznachrichten.de

Reviva Pharmaceuticals Holdings, Inc. Updates Shareholders on Strategic Direction and Brilaroxazine Development

April 15, 2026 | quiverquant.comQ

Reviva Pharmaceuticals Holdings (RVPH) price target decreased by 42.03% to 68.00

April 9, 2026 | msn.com

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of â€œModerate Buyâ€ from Analysts

April 6, 2026 | defenseworld.netD

RVPH: Cleared for Takeoff – 2Q:26 Initiation of RECOVER 2

April 1, 2026 | msn.com

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

March 30, 2026 | globenewswire.com

Reviva Pharmaceuticals Announces One-for-Twenty Reverse Stock Split

March 26, 2026 | theglobeandmail.com

Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock Split

March 25, 2026 | insidermonkey.com

Top 10 Stocks Under $5 That Could Triple

March 24, 2026 | msn.com

Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering

March 23, 2026 | finance.yahoo.com

Reviva Pharmaceuticals Announces $10 Million Equity Offering

March 19, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL, RVPH, CVKD, and ADXN Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$5.66 -0.03 (-0.53%)

As of 12:47 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Artelo Biosciences NASDAQ:ARTL

$0.77 +0.02 (+2.49%)

As of 12:50 PM Eastern

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Cadrenal Therapeutics NASDAQ:CVKD

$1.94 -0.02 (-0.97%)

As of 12:38 PM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.45 0.00 (0.00%)

As of 11:37 AM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARTL, RVPH, CVKD, and ADXN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARTL, RVPH, CVKD, and ADXN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARTL, RVPH, CVKD, and ADXN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL, RVPH, CVKD, and ADXN Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Artelo Biosciences NASDAQ:ARTL

Cadrenal Therapeutics NASDAQ:CVKD

Reviva Pharmaceuticals NASDAQ:RVPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARTL, RVPH, CVKD, and ADXN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARTL, RVPH, CVKD, and ADXN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARTL, RVPH, CVKD, and ADXN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL, RVPH, CVKD, and ADXN Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Artelo Biosciences NASDAQ:ARTL

Cadrenal Therapeutics NASDAQ:CVKD

Reviva Pharmaceuticals NASDAQ:RVPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools